GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | H2ax | increases expression | EXP | | 6480464 | CTD | Cisplatin results in increased expression of H2AX protein modified form | PMID:26739623 | H2ax | multiple interactions | EXP | | 6480464 | CTD | Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form] | PMID:26739623 | H2ax | increases expression | ISO | H2AX (Homo sapiens) | 6480464 | CTD | Cisplatin results in increased expression of H2AX mRNA; Cisplatin results in increased expression of H2AX protein; Cisplatin results in increased expression of H2AX protein modified form | PMID:21500194 PMID:22383522 PMID:22659117 PMID:24994473 PMID:24999622 PMID:25940438 PMID:27594783 PMID:28371273 PMID:29567272 PMID:33545341 PMID:34822033 PMID:37802411 | H2ax | increases expression | ISO | H2ax (Mus musculus) | 6480464 | CTD | Cisplatin results in increased expression of H2AX protein; Cisplatin results in increased expression of H2AX protein modified form | PMID:26723870 PMID:26739623 | H2ax | increases phosphorylation | ISO | H2AX (Homo sapiens) | 6480464 | CTD | Cisplatin results in increased phosphorylation of H2AX protein | PMID:20145152 PMID:21285353 PMID:21324906 PMID:21356574 PMID:21445297 PMID:21875941 PMID:23861973 PMID:26721606 PMID:32482060 PMID:34510228 | H2ax | increases phosphorylation | ISO | H2ax (Mus musculus) | 6480464 | CTD | Cisplatin results in increased phosphorylation of H2AX protein | PMID:21285353 PMID:21593482 PMID:22006019 PMID:26193055 | H2ax | multiple interactions | ISO | H2AX (Homo sapiens) | 6480464 | CTD | (+)-JQ1 compound promotes the reaction [Cisplatin results in increased expression of H2AX protein]; [MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Cisplatin; [Proadifen co-treated with Cisplatin] results in increased phosphorylation of H2AX protein; Arsenic Trioxide inhibits the reaction [SHH protein inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]; BMI1 inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; BRCA1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]]; Cisplatin results in increased phosphorylation of and results in increased ubiquitination of H2AX protein; ERCC1 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]]; ERCC1 mutant form inhibits the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]; ERCC5 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]]; ERCC6 protein inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Cisplatin]; Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; MIR630 mRNA inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; PTEN protein affects the reaction [Cisplatin results in increased expression of H2AX protein]; Quercetin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]; S100A11 mutant form promotes the reaction [Cisplatin results in increased expression of H2AX protein]; SHH protein inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; TP53 protein inhibits the reaction [USP39 protein inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]]; Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein]; USP39 protein inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; XPA mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]] | PMID:20145152 PMID:21324906 PMID:21356574 PMID:21445297 PMID:21693595 PMID:21750216 PMID:21875941 PMID:22383522 PMID:23861973 PMID:24999622 PMID:25940438 PMID:26721606 PMID:29567272 PMID:34822033 PMID:37802411 | H2ax | multiple interactions | ISO | H2ax (Mus musculus) | 6480464 | CTD | erdosteine inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]; Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; PRKDC protein mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein] | PMID:21324906 PMID:26193055 PMID:26739623 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |